Clinical Trial Update: A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment [Phase 3]

View source ↗

Summary

This document reports a multicenter Phase III clinical trial evaluating INR101 Injection for PET/CT imaging in men with suspected recurrent prostate cancer afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• INR101 Injection (INR101)

Snippet

Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd | Conditions: Prostate Cancer Recurrent | Phase 3 | Status: NOT_YET_RECRUITING